Business
Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at ...
Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism
About this update from Celldex Therapeutics, Inc.
[{"type":"text","content":"Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026 \n - Sustained off-treatment efficacy despite barzolvolimab clearance and normalization of tryptase, suggesting disease modification in patients with CSU treated for full 52 weeks -- Greatly improved quality of life and reduced disease impact for patients with ColdU/SD at Week 20 -HAMPTON, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) presented additional positive data from the completed Phase 2 clinical trials of barzolvolimab in chronic spontaneous urticaria (CSU) and cold urticaria (ColdU) and symptomatic dermographism (SD). Barzolvolimab is a humanized monoclonal antibody with a completely novel mechanism of action that uniquely targets the root cause of CSU, ColdU and SD—the mast cell. The data were presented today at the 2026 Allergy, Asthma & Immunology's (AAAAI) Annual Meeting being held in Philadelphia, PA. “Barzolvolimab’s novel mechanism of action uniquely targets the root cause of chronic urticarias—the mast cell—and is driving the unparalleled efficacy we are seeing across our studies in chronic spontaneous urticaria, cold urticaria and symptomatic dermographism,” said Diane Young, MD, Senior Vice President and Chief Medical Officer of Celldex. “The data presented at AAAAI continue to demonstrate that barzolvolimab has the potential to transform the treatment landscape by providing rapid, profound and durable efficacy, including symptom free complete control and dramatic improvements in quality of life and angioedema—offering new hope for the patients suffering from these often severe and debilitating diseases.” Summary of Friday, February 27rd Presentations: Prolonged Off-Treatment Efficacy of Barzolvolimab in Chronic Spontaneous Urticaria; presented by Martin Metz, M.D., Professor, Department of Dermatology and Allergy, Head of Translational Research and Deputy Head of Clinical Trials at Charité – Universitätsmedizin in Berlin Data from the abstract associated with this presentation were also highlighted by AAAAI in a press release issued in early February. As previously reported in the Phase 2 CSU study, up to 51% of patients on study exper...